Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2

被引：0

作者：

Gelmon, Karen ^{[1
]}

Walshe, Janice M. ^{[2
]}

Mahtani, Reshma ^{[3
]}

Joy, Anil A. ^{[4
]}

Karuturi, Meghan ^{[5
]}

Neven, Patrick ^{[6
]}

Lu, Dongrui Ray ^{[7
]}

Kim, Sindy ^{[7
]}

Schnell, Patrick ^{[8
]}

Bananis, Eustratios ^{[8
]}

Schwartzberg, Lee ^{[9
]}

机构：

[1] British Columbia Canc Ctr, Vancouver, BC, Canada

[2] Canc Trials Ireland, Dublin, Ireland

[3] Univ Miami, Sylvester Canc Ctr, Deerfield Beach, FL USA

[4] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] UZ Leuven, Breast Clin, Leuven, Belgium

[7] Pfizer Inc, San Diego, CA USA

[8] Pfizer Inc, New York, NY USA

[9] West Canc Ctr, Germantown, TN USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS10-14

引用

页数：1

共 50 条

[1] Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
Gelmon, Karen
Walshe, Janice M.
Mahtani, Reshma
Joy, Anil A.
Karuturi, Meghan
Neven, Patrick
Lu, Dongrui Ray
Kim, Sindy
Schnell, Patrick
Bananis, Eustratios
Schwartzberg, Lee
[J]. BREAST, 2021, 59 : 321 - 326
[2] Efficacy and safety of palbociclib (PAL) plus letrozole (LET) as first-line therapy in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2
Gelmon, Karen A.
Castrellon, Aurelio
Joy, Anil A.
Walshe, Janice M.
Ettl, Johannes
Mukai, Hirofumi
Park, In Hae
Lu, Dongrui R.
Mori, Ave
Bananis, Eustratios
Dieras, Veronique
Finn, Richard S.
[J]. CANCER RESEARCH, 2018, 78 (04)
[3] Impact of prior treatment on palbociclib plus letrozole (P plus L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis
Finn, R. S.
Gelmon, K. A.
Ettl, J.
Asselah, J.
Castrellon, A.
Ruiz Simon, A.
Joy, A. A.
Lu, D.
Gauthier, E. R.
Mori, A.
Rugo, H. S.
Dieras, V.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[4] PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib plus letrozole (P plus L)
Dieras, V.
Harbeck, N.
Joy, A. A.
Gelmon, K. A.
Ettl, J.
Verma, S.
Lu, D.
Gauthier, E. R.
Schnell, P.
Mori, A.
Rugo, H. S.
Finn, R. S.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[5] Clinical outcomes in patients (pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with objective response (OR) or without objective response (non-OR) in PALOMA-2
Rugo, H. S.
Finn, R. S.
Gelmon, K. A.
Joy, A. A.
Lipatov, O. N.
Harbeck, N.
Castrellon, A.
Mukai, H.
Walshe, J. M.
Mori, A.
Gauthier, E.
Lu, D. R.
Bananis, E.
Martin, M.
Dieras, V.
[J]. ANNALS OF ONCOLOGY, 2018, 29 : 107 - +
[6] Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Mukai, Hirofumi
Shimizu, Chikako
Masuda, Norikazu
Ohtani, Shoichiro
Ohno, Shinji
Takahashi, Masato
Yamamoto, Yutaka
Nishimura, Reiki
Sato, Nobuaki
Ohsumi, Shozo
Iwata, Hiroji
Mori, Yuko
Hashigaki, Satoshi
Muramatsu, Yasuaki
Nagasawa, Takashi
Umeyama, Yoshiko
Lu, Dongrui R.
Toi, Masakazu
[J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (03) : 274 - 287
[7] Effect of palbociclib (PAL) plus endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)
Rugo, H. S.
Im, S-A.
Joy, A. A.
Yaroslav, S.
Walshe, J. M.
Sleckman, B.
Loi, S.
Puyana Theall, K.
Kim, S.
Huang, X.
Bananis, E.
Mahtani, R.
Finn, R. S.
Dieras, V.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S461 - S461
[8] Palbociclib (PAL) plus letrozole (L) as first-line (1) therapy (tx) in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups.
Finn, Richard S.
Dieras, Veronique
Rugo, Hope S.
Joy, Anil A.
Moulder, Stacy L.
Walshe, Janice Maria
Mukai, Hirofumi
Shparyk, Yaroslav V.
Park, In Hae
Mori, Ave
Lu, Dongrui
Gauthier, Eric Roland
Gelmon, Karen A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] Alpelisib plus letrozole in estrogen receptor-Positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC): Safety and preliminary efficacy analysis from a phase 1b trial
Juric, Dejan
Goncalves, Anthony
Hamilton, Erika
Boni, Valentina
Mayer, Ingrid A.
Turri, Sabine
Wang, Yingbo
Vogl, Florian D.
Sellami, Dalila
Campone, Mario
[J]. CANCER RESEARCH, 2018, 78 (04)
[10] Palbociclib (PAL) plus letrozole (LET) as first-line therapy in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups
Rugo, Hope S.
Finn, Richard S.
Dieras, Veronique
Ettl, Johannes
Lipatov, Oleg
Joy, Anil
Harbeck, Nadia
Castrellon, Aurelio
Lu, Dongrui R.
Mori, Ave
Gauthier, Eric R.
Huang, Cynthia
Gelmon, Karen A.
Slamon, Dennis J.
[J]. CANCER RESEARCH, 2018, 78 (04)

← 1 2 3 4 5 →